Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2)

Exclusion criteria

• ✕. Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum human chorionic gonadotrophin laboratory test (\> 5 mIU/mL). Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means, unless they met the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels \> 40 mIU/mL or were using one or more of the following acceptable methods of contraception:
• ✕. Surgical sterilization (e.g. bilateral tubal ligation, hysterectomy);
• ✕. Hormonal contraception (implantable, patch, oral);
• ✕. Double-barrier methods (any double combination of: IUD, male or female condom, diaphragm, sponge, cervical cap).
• ✕. Body Mass Index (BMI) \> 34 kg/m2;
• ✕. Patients with lower respiratory tract infections affecting the patient's asthma within 30 days of the screening visit;
• ✕. Use of systemic steroids in the last month;
• ✕. Patients with other lung diseases such as (but not limited to) COPD, cystic fibrosis, interstitial lung diseases or any other clinically or functionally significant lung disorder;